ArticleBMC pharmacology & toxicology2026
A retrospective study of the efficacy and safety of rituximab biosimilar for the treatment of membranous nephropathy.
Article in BMC pharmacology & toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundRituximab (RTX) is a monoclonal antibody that targets CD20 and is recommended by the KDIGO guidelines as a first-line treatment for membranous nephropathy (MN). The RTX biosimilar (HLX01) was the first biosimilar licensed in China in 2019. However, its efficacy and safety for MN treatment remain unclear. This study aimed to evaluate the performance of the RTX biosimilar for MN in a real-world setting.
methodsIn this study, the medical records of 201 MN inpatients treated with high-dose RTX biosimilar and followed up for one year from January 2020 to December 2022 at PUMCH were retrospectively collected. Efficacy was evaluated in accordance with the KDIGO guidelines. Adverse reactions recorded in medical records during or after infusion were collected.
resultsDuring the one-year follow-up period, the overall remission rate of high-dose RTX biosimilar treatment for MN was 75.12% (151/201), with 53 patients achieving complete remission and 98 patients reaching partial remission. The median time to remission was 6 months. Among patients who achieved remission, the relapse rate was 7.95% (12/151), among whom 7 patients achieved remission again after readministration. The remission rate was 78.79% (52/66) for treatment-naïve patients and 73.33% (99/135) for treated patients (P = 0.401). Adverse events included pruritus, flushing, hypotension, fever, rash, oropharyngeal discomfort, chest distress, eyelid edema, nausea and vomiting, and nasal congestion or rhinorrhea, with an overall incidence of 30.85% (62/201).
conclusionsRituximab biosimilar has acceptable efficacy and safety in patients with MN, and their outcomes are similar to those of innovator RTX products reported in the literature. Thus, it may be used as an alternative to the innovator RTX as a first-line treatment for MN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.